Human Babesiosis in Metropolitan France

计划入组 100 人 · 首次发布于 2026 年 1 月 16 日

B-FREE Chronic Babesiosis Study

计划入组 40 人 · 首次发布于 2024 年 10 月 24 日

Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis

计划入组 33 人 · 首次发布于 2024 年 1 月 17 日

Canine AAV8-MTM1 vector

PEGylated Recombinant Canine Human Uricase

Pegylated recombinant canine human uricase (Shandong New Time Pharmaceutical)

CONNIE PRICE

United States

Welffens Karine

Belgium

CARINA BIOTECH LIMITED

Australia

60 Degrees Pharmaceuticals Seeks FDA MUMS Designation for First Oral Canine Babesiosis Treatment

60 Degrees Pharma's Tafenoquine Study for Babesiosis in Immunocompromised Patients Gains IRB Approval

60 Degrees Pharma's Tafenoquine Receives IRB Approval for Phase II Chronic Babesiosis Study